Warnex's Influenza A H1N1 Virus Test will be Distributed by Biron
News Sep 11, 2009
Warnex Inc. has announced that its Medical Laboratories division has signed a distribution agreement with Biron-Laboratoire medical, a Quebec-based provider of diagnostic and medical treatment services.
According to the terms of the agreement, Biron will promote and distribute Warnex's test for the influenza A H1N1 virus, specifically targeting industrial companies.
"With the possibility of a significant incidence rate of the pandemic A H1N1 flu virus this fall, companies are increasingly concerned with the effect this might have on their workforce," said Mark Busgang, President and CEO of Warnex. "With Warnex's test for the A H1N1 flu virus, which offers results in as little as 8 hours, employees may receive diagnosis earlier, allowing company decision makers to rapidly take appropriate action to limit the spread of infection to the rest of their workforce."
"Biron has a strong corporate and industrial presence and we are proud to offer the A H1N1 diagnostic test to these clients. Along with the seasonal influenza vaccination, still recommended by the World Health Organization, the A H1N1 diagnostic test will offer our clients the best tool currently available to better control a pandemic situation in the workplace," said Eve-Lyne Biron, President of Biron-Laboratoire medical. Unfortunately, the availability of the A H1N1 vaccine is not yet determined."
Influenza A H1N1 virus, also known as human swine flu, is a variant of the influenza A virus which was first detected in people in April 2009 and has been declared a pandemic by the World Health Organization. The A H1N1 flu virus spreads from person to person, probably in much the same way as regular seasonal influenza viruses.
Warnex uses RT-PCR technology to specifically detect the influenza A virus including the A H1N1 strain. Warnex offers an accelerated service whereby results are provided in as little as 8 hours. Warnex also recently launched a test that specifically detects the H275Y mutation of the pandemic influenza A H1N1 virus, which is associated with resistance to Tamiflu®, a drug used for the treatment and prevention of the flu.
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019